Italia markets close in 3 hours 10 minutes

Quantum Genomics Société Anonyme (0D1J.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
2,8840+0,1131 (+4,08%)
Al 10:42AM BST. Mercato aperto.
Schermo intero
Chiusura precedente2,7709
Aperto2,8840
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno2,8840 - 2,8840
Intervallo di 52 settimane2,8840 - 2,8840
Volume3.500
Media VolumeN/D
Capitalizzazione491.589
Beta (5 anni mensile)1,02
Rapporto PE (ttm)N/D
EPS (ttm)-0,6030
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Quantum Genomics announces the appointment of its new Scientific Advisory Board

    PARIS, June 27, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat hypertension and heart failure, today announces the appointment of new members of its Scientific Advisory Board. Professor George L. Bakris (Chicago, US), Professor Gregory Y. H. Lip (Liverpool, UK) and Professor Atul Pathak (Monaco) are joining Prof. Keith C. Ferdinand and Prof. A

  • GlobeNewswire

    Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

    PARIS, May 09, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat hypertension and heart failure, announces today that it has recruited all planned patients in its phase III pivotal study FRESH, which aims to evaluate firibastat’s efficacy in the treatment of difficult-to-treat1 and resistant2 hypertension. "We’re delighted to have completed recru

  • GlobeNewswire

    Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

    PARIS, May 04, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat difficult-to-treat/resistant hypertension and heart failure, announces it is strengthening its leadership team with the appointment of Sarah Merlen-Boulenger as Head of Regulatory Affairs. Sarah Merlen-Boulenger joins Quantum Genomics to lead the preparation of firibastat’s registra